News / Events

Cryoport and EVERSANA Form Strategic Alliance to Accelerate Regenerative Medicine Supply Chain

IRVINE, California, July 11, 2019 – Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) and EVERSANA™ have announced a strategic alliance to further create a fully integrated regenerative medicine supply chain solution. The alliance will be designed to leverage EVERSANA’s position as the leading provider of commercial services addressing access, affordability and adherence challenges for cell and gene therapies and Cryoport’s complete suite of temperature-controlled logistics solutions to ensure a safe and effective supply chain solution for innovative therapeutic advancements.

This broad-based strategic alliance will be offered to current and prospective clients to support the development of groundbreaking regenerative medicines, including CAR T-cell and gene therapies.

“The promise of regenerative medicine requires an innovative look at the complete product life cycle from market access planning through efficient distribution and best-in-class patient support. With Cryoport, we add real time logistics solutions with its standard setting Chain of Compliance™, which includes “chain of condition”, “chain of custody” and “chain of identity”, to our global distribution and patient service capabilities,” said Jim Lang, EVERSANA CEO. “Their temperature-controlled logistics solutions are currently used by almost all of the leading biopharma companies. Our alliance will drive synergistic revenue growth for both of our companies and provide synergistic value to our clients.”

Jerrell Shelton, Cryoport CEO added, “Through our alliance, Cryoport will provide EVERSANA and its clients with our full suite of logistics solutions under our ‘powered by cryoport’ marketing model. This includes our Cryoport Express® Shippers, Cryoportal® Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and our advanced logistics management. EVERSANA is building a powerhouse, currently serving over 500 life sciences companies, over 100 therapeutics areas, including cell and gene therapies, across 80 countries. As we continue to systematically develop our technologies and services, our alliance will enable us to broaden the distribution of our solutions and more broadly answer demand from regenerative medicine companies for temperature-controlled for supply chain services. We are proud to partner with EVERSANA to offer an advanced integrated supply chain solution to our collective base of clients. The regenerative therapy market is in its infancy with support requirements evolving and this alliance is designed to capture the vast opportunities at the “head of the stream.’”

 

About Cryoport, Inc.

Cryoport is the life sciences industry’s most trusted global provider of temperature-controlled logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR-T cells. Cryoport also provides a range of bioservices to the life sciences industry, including biostorage for biological specimens, materials and samples.  Cryoport’s solutions are used by points-of-care, CRO’s, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport’s proprietary Cryoport Express® Shippers, Cryoportal® Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts. Cryoport is dedicated to: simplifying global cold chain logistics through innovative technology, unmatched monitoring and data capture and support, including consulting; delivering the most advanced temperature-controlled logistics solutions for the life sciences industry; and providing vital information that provides peace of mind throughout the life of each logistics process.

For more information, visit www.cryoport.com. Sign up to follow @cryoport on Twitter at www.twitter.com/cryoport.

 

About EVERSANA™

EVERSANA™ is the leading independent provider of global services to the life science industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product lifecycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies to advance life science solutions for a healthier world. To learn more about EVERSANA, visit EVERSANA.com or connect through LinkedIn and Twitter.

 

Forward Looking Statements

Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company’s cash flow, market acceptance risks, and technical development risks. The Company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the Company’s SEC reports including, but not limited to, the Company’s 10-K for the year ended December 31, 2018 filed with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

 

For Cryoport:

Todd Fromer/Elizabeth Barker
tfromer@kcsa.com/ebarker@kcsa.com
P: 1 212-896-1203

 

For EVERSANA:

Sarah Zwicky
sarah.zwicky@eversana.com
P: 1 414-434-4691

###

EVERSANA™ names life sciences digital leader Bhaskar Sambasivan to lead Patient Services

CHICAGO – June 27, 2019 – EVERSANA™, the leading independent provider of global commercial services to the life science industry, today announced the appointment of Bhaskar Sambasivan to President, Patient Services and Chief Strategy Officer. Widely recognized as a global leader in life sciences, Sambasivan blends his commitment to best-in-class patient services with expertise leading […]

EVERSANA Sponsors the 15th Annual Commercial Contract and Chargeback Excellence

EVERSANA is a sponsor at the 15th Annual Commercial Contract and Chargeback Excellence conference on June 25-26, 2019, taking place in Philadelphia, PA. Join Robert Blank, Managing Consultant, as he moderates a panel with industry experts from Sanofi, Zydus, and UCB. Panel: “Process Improvement in Contract Administration and Management — Streamlining Chargeback Operations, GPO Rosters […]

EVERSANA™ acquires Alamo Pharma Services and BexR Logistix Telesales to add robust field solutions into growing life science commercial services platform

CHICAGO  – May 28, 2019  – EVERSANA,™ the leading independent provider of commercial services to the life science industry, today announced the acquisition of Alamo Pharma Services®, Inc. and BexR Logistix®, LLC Telesales from Mission Pharmacal® Company. Headquartered in Doylestown, Pa., Alamo is a leader in field sales, marketing and clinical solutions for pharmaceutical and […]

EVERSANA Co-Sponsors Advanced Therapies & Regenerative Medicine Congress and Expo

We are excited to be a co-sponsor of the upcoming Advanced Therapies & Regenerative Medicine Congress & Expo. The conference will be held from May 15-17 in London, UK. Scott Clark, SVP for Global Strategic Alliances, will join a panel of esteemed industry thought leaders – from Cryoport, Mesoblast and UC Davis Health – in […]

EVERSANA Sponsors ISPOR New Orleans 2019

EVERSANA proudly announces our participation at ISPOR New Orleans as a Bronze Sponsor. ISPOR 2019, held May 18-22 in New Orleans, LA, is the leading global conference for Health Economics and Outcomes Research. This year’s conference theme: A New Era in HEOR connects the continual shift in the global healthcare landscape with essential developments in […]

EVERSANA and OptimizeRx Partner to Deliver High Tech and High Touch Pharmaceutical Services

Las Vegas, Nev. — April 30, 2019 – EVERSANA™, the leading independent provider of global services to the life science industry, and OptimizeRx Corp. (NASDAQ: OPRX), a leading digital health messaging platform focused on affordability and adherence, today announced their partnership to modernize the patient experience and improve health outcomes by combining a real-time electronic […]

EVERSANA™ doubles cold chain storage capabilities to serve transformative life science therapy advancements

Chicago, IL – April 29, 2019 – EVERSANA,™ the leading independent provider of global services to the life science industry, today announced that expansions to its cold chain storage capabilities are complete and ready to meet the growing 3PL and complex channel distribution needs of the pharmaceutical industry. The investment doubles the company’s refrigeration capabilities […]

How UK Payers view Biosimilar Hurdles

Over the last several years, market demand for biosimilars has accelerated particularly for high value reference products. Efforts have been undertaken to provide education, experience sharing platforms as well as coordinating tenders across regions in the UK. Given the success of these strategies in terms of market share penetration are there really any barriers which […]

EVERSANA Sponsors the 21st Annual CBI Medicaid and Government Pricing Congress

EVERSANA is a premier sponsor at the 21st Annual Medicaid and Government Pricing Congress on May 20-22, 2019, taking place in Orlando, Florida. Meet our team of experts who will be part of the discussion. Michael Kurland, VP, Revenue Management & Compliance Solutions Tuesday, May 21 at 4:45 pm Workshop G: Large Pharma (panelist) Joseph Birdsall, […]